Dicerna
Race for hepatitis B drug intensifies as Antios raises $96m for phase 2 trial
Richard Staines
Antios, Dicerna, GlaxoSmithKline, hepatitis B, infectious diseases, Ionis, Roche
0 Comment
Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit
Phil Taylor
Diabetes, Dicerna, gene silencing, hepatology, NASH, Novo Nordisk, RNAi
0 Comment
FDA approves Alnylam’s ultra-rare disease drug Oxlumo
Richard Staines
Alnylam, Dicerna, pricing, Rare diseases, regulation
0 Comment
Alnylam files its third RNAi drug lumasiran in rare kidney disease
Phil Taylor
Alnylam, Dicerna, lumasiran, nephrology, OxThera, rare disease
0 Comment
Novo bolsters R&D pipeline with RNAi therapies from Dicerna
Richard Staines
Dicerna, NASH, Novo Nordisk, RNAi therapy
0 Comment
Roche swoops on Dicerna’s gene-silencing hepatitis B drug
Phil Taylor
Dicerna, hepatitis B, licensing, RNA interference, Roche
0 Comment
Alexion joins with Dicerna to develop RNAi therapies for complement diseases
Richard Staines
Alexion, Dicerna, R&D, Rare diseases
0 Comment